{"pmid":32431818,"pmcid":"PMC7201274","title":"Visualizing an unseen enemy; mobilizing structural biology to counter COVID-19.","text":["Visualizing an unseen enemy; mobilizing structural biology to counter COVID-19.","Crystallography in its broadest sense has a crucial role to play in addressing the current COVID-19 pandemic. An outpouring of structural information on key viral proteins has resulted and importantly these data have immediately been shared with researchers round the world to speed the discovery of effective therapeutic agents.","IUCrJ","Baker, Edward N","32431818"],"abstract":["Crystallography in its broadest sense has a crucial role to play in addressing the current COVID-19 pandemic. An outpouring of structural information on key viral proteins has resulted and importantly these data have immediately been shared with researchers round the world to speed the discovery of effective therapeutic agents."],"journal":"IUCrJ","authors":["Baker, Edward N"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32431818","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1107/S2052252520004571","keywords":["covid-19","sars-cov-2","coronaviruses","editorial"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1667342288296083456,"score":9.490897,"similar":[{"pmid":32254054,"pmcid":"PMC7137107","title":"Visualizing an unseen enemy; mobilizing structural biology to counter COVID-19.","text":["Visualizing an unseen enemy; mobilizing structural biology to counter COVID-19.","Acta Crystallogr D Struct Biol","Baker, Edward N","32254054"],"journal":"Acta Crystallogr D Struct Biol","authors":["Baker, Edward N"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32254054","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1107/S2059798320004830","keywords":["covid-19","sars-cov-2","coronaviruses","editorial"],"topics":["Mechanism"],"weight":1,"_version_":1666138493172056065,"score":311.67758},{"pmid":32254048,"pmcid":"PMC7137381","title":"Visualizing an unseen enemy; mobilizing structural biology to counter COVID-19.","text":["Visualizing an unseen enemy; mobilizing structural biology to counter COVID-19.","Acta Crystallogr F Struct Biol Commun","Baker, Edward N","32254048"],"journal":"Acta Crystallogr F Struct Biol Commun","authors":["Baker, Edward N"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32254048","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1107/S2053230X20004847","keywords":["covid-19","sars-cov-2","coronaviruses","editorial"],"topics":["Mechanism"],"weight":1,"_version_":1666138493173104641,"score":311.67758},{"pmid":32105468,"pmcid":"PMC7094172","title":"Structure-Based Stabilization of Non-native Protein-Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design.","text":["Structure-Based Stabilization of Non-native Protein-Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design.","Structure-based stabilization of protein-protein interactions (PPIs) is a promising strategy for drug discovery. However, this approach has mainly focused on the stabilization of native PPIs, and non-native PPIs have received little consideration. Here, we identified a non-native interaction interface on the three-dimensional dimeric structure of the N-terminal domain of the MERS-CoV nucleocapsid protein (MERS-CoV N-NTD). The interface formed a conserved hydrophobic cavity suitable for targeted drug screening. By considering the hydrophobic complementarity during the virtual screening step, we identified 5-benzyloxygramine as a new N protein PPI orthosteric stabilizer that exhibits both antiviral and N-NTD protein-stabilizing activities. X-ray crystallography and small-angle X-ray scattering showed that 5-benzyloxygramine stabilizes the N-NTD dimers through simultaneous hydrophobic interactions with both partners, resulting in abnormal N protein oligomerization that was further confirmed in the cell. This unique approach based on the identification and stabilization of non-native PPIs of N protein could be applied toward drug discovery against CoV diseases.","J Med Chem","Lin, Shan-Meng","Lin, Shih-Chao","Hsu, Jia-Ning","Chang, Chung-Ke","Chien, Ching-Ming","Wang, Yong-Sheng","Wu, Hung-Yi","Jeng, U-Ser","Kehn-Hall, Kylene","Hou, Ming-Hon","32105468"],"abstract":["Structure-based stabilization of protein-protein interactions (PPIs) is a promising strategy for drug discovery. However, this approach has mainly focused on the stabilization of native PPIs, and non-native PPIs have received little consideration. Here, we identified a non-native interaction interface on the three-dimensional dimeric structure of the N-terminal domain of the MERS-CoV nucleocapsid protein (MERS-CoV N-NTD). The interface formed a conserved hydrophobic cavity suitable for targeted drug screening. By considering the hydrophobic complementarity during the virtual screening step, we identified 5-benzyloxygramine as a new N protein PPI orthosteric stabilizer that exhibits both antiviral and N-NTD protein-stabilizing activities. X-ray crystallography and small-angle X-ray scattering showed that 5-benzyloxygramine stabilizes the N-NTD dimers through simultaneous hydrophobic interactions with both partners, resulting in abnormal N protein oligomerization that was further confirmed in the cell. This unique approach based on the identification and stabilization of non-native PPIs of N protein could be applied toward drug discovery against CoV diseases."],"journal":"J Med Chem","authors":["Lin, Shan-Meng","Lin, Shih-Chao","Hsu, Jia-Ning","Chang, Chung-Ke","Chien, Ching-Ming","Wang, Yong-Sheng","Wu, Hung-Yi","Jeng, U-Ser","Kehn-Hall, Kylene","Hou, Ming-Hon"],"date":"2020-02-28T11:00:00Z","year":2020,"_id":"32105468","source":"PubMed","week":"20209|Feb 24 - Mar 01","doi":"10.1021/acs.jmedchem.9b01913","e_drugs":["5-benzyloxygramine"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490789691392,"score":122.711044},{"pmid":32418327,"title":"Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank.","text":["Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank.","A bright spot in the SARS-CoV-2 (CoV-2) coronavirus pandemic has been the immediate mobilization of the biomedical community, working to develop treatments and vaccines for COVID-19. Rational drug design against emerging threats depends on well-established methodology, mainly utilizing X-ray crystallography, to provide accurate structure models of the macromolecular drug targets and of their complexes with candidates for drug development. In the current crisis the structural biological community has responded by presenting structure models of CoV-2 proteins and depositing them in the Protein Data Bank (PDB), usually without time embargo and before publication. Since the structures from the first-line research are produced in an accelerated mode, there is an elevated chance of mistakes and errors, with the ultimate risk of hindering, rather than speeding-up, drug development. In the present work, we have used model-validation metrics and examined the electron density maps for the deposited models of CoV-2 proteins and a sample of related proteins available in the PDB as of 1 April 2020. We present these results with the aim of helping the biomedical community establish a better-validated pool of data. The proteins are divided into groups according to their structure and function. In most cases, no major corrections were necessary. However, in several cases significant revisions in the functionally sensitive area of protein-inhibitor complexes or for bound ions justified correction, re-refinement, and eventually re-versioning in the PDB. The re-refined coordinate files and a tool for facilitating model comparisons are available at https://covid-19.bioreproducibility.org.","FEBS J","Wlodawer, Alexander","Dauter, Zbigniew","Shabalin, Ivan","Gilski, Miroslaw","Brzezinski, Dariusz","Kowiel, Marcin","Minor, Wladek","Rupp, Bernhard","Jaskolski, Mariusz","32418327"],"abstract":["A bright spot in the SARS-CoV-2 (CoV-2) coronavirus pandemic has been the immediate mobilization of the biomedical community, working to develop treatments and vaccines for COVID-19. Rational drug design against emerging threats depends on well-established methodology, mainly utilizing X-ray crystallography, to provide accurate structure models of the macromolecular drug targets and of their complexes with candidates for drug development. In the current crisis the structural biological community has responded by presenting structure models of CoV-2 proteins and depositing them in the Protein Data Bank (PDB), usually without time embargo and before publication. Since the structures from the first-line research are produced in an accelerated mode, there is an elevated chance of mistakes and errors, with the ultimate risk of hindering, rather than speeding-up, drug development. In the present work, we have used model-validation metrics and examined the electron density maps for the deposited models of CoV-2 proteins and a sample of related proteins available in the PDB as of 1 April 2020. We present these results with the aim of helping the biomedical community establish a better-validated pool of data. The proteins are divided into groups according to their structure and function. In most cases, no major corrections were necessary. However, in several cases significant revisions in the functionally sensitive area of protein-inhibitor complexes or for bound ions justified correction, re-refinement, and eventually re-versioning in the PDB. The re-refined coordinate files and a tool for facilitating model comparisons are available at https://covid-19.bioreproducibility.org."],"journal":"FEBS J","authors":["Wlodawer, Alexander","Dauter, Zbigniew","Shabalin, Ivan","Gilski, Miroslaw","Brzezinski, Dariusz","Kowiel, Marcin","Minor, Wladek","Rupp, Bernhard","Jaskolski, Mariusz"],"date":"2020-05-18T11:00:00Z","year":2020,"_id":"32418327","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/febs.15366","keywords":["covid-19","protein data bank (pdb)","sars-cov-2","coronavirus","ligand validation","spike glycoprotein","structure-guided drug discovery","viral proteases"],"locations":["Ligand"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1667058206854086656,"score":116.96417},{"pmid":32272481,"title":"Structure of M(pro) from COVID-19 virus and discovery of its inhibitors.","text":["Structure of M(pro) from COVID-19 virus and discovery of its inhibitors.","A new coronavirus (CoV) identified as COVID-19 virus is the etiological agent responsible for the 2019-2020 viral pneumonia outbreak that commenced in Wuhan(1-4). Currently there are no targeted therapeutics and effective treatment options remain very limited. In order to rapidly discover lead compounds for clinical use, we initiated a program of combined structure-assisted drug design, virtual drug screening and high-throughput screening to identify new drug leads that target the COVID-19 virus main protease (M(pro)). M(pro) is a key CoV enzyme, which plays a pivotal role in mediating viral replication and transcription, making it an attractive drug target for this virus(5,6). Here, we identified a mechanism-based inhibitor, N3, by computer-aided drug design and subsequently determined the crystal structure of COVID-19 virus M(pro) in complex with this compound. Next, through a combination of structure-based virtual and high-throughput screening, we assayed over 10,000 compounds including approved drugs, drug candidates in clinical trials, and other pharmacologically active compounds as inhibitors of M(pro). Six of these compounds inhibited M(pro) with IC50 values ranging from 0.67 to 21.4 muM. Ebselen also exhibited promising antiviral activity in cell-based assays. Our results demonstrate the efficacy of this screening strategy, which can lead to the rapid discovery of drug leads with clinical potential in response to new infectious diseases for which no specific drugs or vaccines are available.","Nature","Jin, Zhenming","Du, Xiaoyu","Xu, Yechun","Deng, Yongqiang","Liu, Meiqin","Zhao, Yao","Zhang, Bing","Li, Xiaofeng","Zhang, Leike","Peng, Chao","Duan, Yinkai","Yu, Jing","Wang, Lin","Yang, Kailin","Liu, Fengjiang","Jiang, Rendi","Yang, Xinglou","You, Tian","Liu, Xiaoce","Yang, Xiuna","Bai, Fang","Liu, Hong","Liu, Xiang","Guddat, Luke W","Xu, Wenqing","Xiao, Gengfu","Qin, Chengfeng","Shi, Zhengli","Jiang, Hualiang","Rao, Zihe","Yang, Haitao","32272481"],"abstract":["A new coronavirus (CoV) identified as COVID-19 virus is the etiological agent responsible for the 2019-2020 viral pneumonia outbreak that commenced in Wuhan(1-4). Currently there are no targeted therapeutics and effective treatment options remain very limited. In order to rapidly discover lead compounds for clinical use, we initiated a program of combined structure-assisted drug design, virtual drug screening and high-throughput screening to identify new drug leads that target the COVID-19 virus main protease (M(pro)). M(pro) is a key CoV enzyme, which plays a pivotal role in mediating viral replication and transcription, making it an attractive drug target for this virus(5,6). Here, we identified a mechanism-based inhibitor, N3, by computer-aided drug design and subsequently determined the crystal structure of COVID-19 virus M(pro) in complex with this compound. Next, through a combination of structure-based virtual and high-throughput screening, we assayed over 10,000 compounds including approved drugs, drug candidates in clinical trials, and other pharmacologically active compounds as inhibitors of M(pro). Six of these compounds inhibited M(pro) with IC50 values ranging from 0.67 to 21.4 muM. Ebselen also exhibited promising antiviral activity in cell-based assays. Our results demonstrate the efficacy of this screening strategy, which can lead to the rapid discovery of drug leads with clinical potential in response to new infectious diseases for which no specific drugs or vaccines are available."],"journal":"Nature","authors":["Jin, Zhenming","Du, Xiaoyu","Xu, Yechun","Deng, Yongqiang","Liu, Meiqin","Zhao, Yao","Zhang, Bing","Li, Xiaofeng","Zhang, Leike","Peng, Chao","Duan, Yinkai","Yu, Jing","Wang, Lin","Yang, Kailin","Liu, Fengjiang","Jiang, Rendi","Yang, Xinglou","You, Tian","Liu, Xiaoce","Yang, Xiuna","Bai, Fang","Liu, Hong","Liu, Xiang","Guddat, Luke W","Xu, Wenqing","Xiao, Gengfu","Qin, Chengfeng","Shi, Zhengli","Jiang, Hualiang","Rao, Zihe","Yang, Haitao"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32272481","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1038/s41586-020-2223-y","e_drugs":["ebselen"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138491833024514,"score":107.24146}]}